James E. Flynn - 19 May 2026 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Reporting relationship: Director, * Director by Deputization, 10%+ Owner
Issuer ticker: LRMR
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2026, 20:02:48 UTC
Prior SEC filing: 02 Mar 2026
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 20 May 2026.

Key facts

This page summarizes James E. Flynn's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 20 May 2026, 20:02.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001352546 Primary reporting owner

Flynn James E

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 20 May 2026

CIK 0001009258

DEERFIELD MANAGEMENT COMPANY, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 20 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LRMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +55,150
Change %
Price: $0.000000^*
Shares after: 55,150
Date: 19 May 2026
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Common Stock
Underlying amount: 55,150
Exercise price: $3.33
Footnotes: F1, F2, F3

LRMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +55,150
Change %
Price: $0.000000^*
Shares after: 55,150
Date: 19 May 2026
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Common Stock
Underlying amount: 55,150
Exercise price: $3.33
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Jonathan S. Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. The option granted to Jonathan S. Leff and reported herein is held for the benefit, and at the direction, of Deerfield Management Company, L.P. ("Deerfield Management").

Footnote F2

The option was granted on May 19, 2026 and is scheduled to vest on the earlier of May 19, 2027 and the date of the Issuer's next annual meeting of stockholders, in each case, subject to Jonathan S. Leff 's continued service on the board of directors of the Issuer.

Footnote F3

This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management Company, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC remarks

Jonathan S. Leff, a partner in Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.